Tilsotolimod - New Trial ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1610 of 1636  at  2/24/2020 8:14:34 PM  by


 In response to msg 1609 by  auh2oman
view thread

Re: Tilsotolimod - New Trial ...

Did I not suggest just exactly this some time ago? About time. This study will show the maximum efficacy possible for TLR9 agonist. This is the smartest study Idera has/will attempt. All cancer therapies have to include a anti-CTLA4 and a anti-PD1. There is no choice. All other biotechs have finally figured this out. If you stimulate the APC/DCís to present antigens to CD8+T cells then the Treg cells will come and spray CTLA4 on the CD80/86 ligands on the APC/DCís....preventing antigen presentation..,tregs trying to prevent autoimmune disease...mistakenly. But if you get past this and present antigens to the CD8+Tís then the CD8+Tís are ready to attack any cancer cell with those cancer specific antigens....but not before they produce IFN gamma cytokines and alert the body that the immune system went active....which causes normal and cancer cells to raise up and express PDL1 ligands which shuts the CD8+Tís back down....the second anti-autoimmune disease self defense system.

I have said this for sometime. Finally someone listened.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 142
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
1611 Re: Tilsotolimod - New Trial ... vorlon1966 0 2/24/2020 8:37:00 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by